Advertisement
Australia markets close in 24 minutes
  • ALL ORDS

    8,212.30
    +45.90 (+0.56%)
     
  • ASX 200

    7,976.10
    +44.40 (+0.56%)
     
  • AUD/USD

    0.6633
    -0.0013 (-0.19%)
     
  • OIL

    79.95
    +0.17 (+0.21%)
     
  • GOLD

    2,395.90
    +1.20 (+0.05%)
     
  • Bitcoin AUD

    100,272.04
    -1,712.30 (-1.68%)
     
  • CMC Crypto 200

    1,367.96
    -37.38 (-2.66%)
     
  • AUD/EUR

    0.6088
    -0.0009 (-0.14%)
     
  • AUD/NZD

    1.1110
    +0.0003 (+0.03%)
     
  • NZX 50

    12,425.58
    +115.67 (+0.94%)
     
  • NASDAQ

    19,822.87
    +300.25 (+1.54%)
     
  • FTSE

    8,198.78
    +43.06 (+0.53%)
     
  • Dow Jones

    40,415.44
    +127.91 (+0.32%)
     
  • DAX

    18,407.07
    +235.14 (+1.29%)
     
  • Hang Seng

    17,565.15
    -70.73 (-0.40%)
     
  • NIKKEI 225

    39,657.08
    +58.08 (+0.15%)
     

Opthea To Present at SVB Leerink Global Biopharma Conference

Opthea Limited
Opthea Limited

MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at SVB Leerink’s Global Biopharma Conference being held virtually on February 14-16, 2023.

Dr. Baldwin’s presentation will take place on Wednesday February 15th at 5:00 pm ET (9:00 am AEDT). An archive of the presentation will be available at https://www.opthea.com/presentations/.

About Opthea Limited

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

ADVERTISEMENT

Inherent risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.

Authorized for release to ASX by Megan Baldwin, CEO & Managing Director

Company & Media Enquiries:

 

 

 

U.S.A. & International:

 

Australia: 

Timothy E. Morris, CFO

 

Rudi Michelson

Opthea Limited

 

Monsoon Communications

Tel: +1 650-400-6874

 

Tel: +61 (0) 3 9620 3333

 

 

 

Media:

 

 

Hershel Berry

 

 

Blueprint Life Science Group

 

 

Tel: +1 415-505-3749

 

 

hberry@bplifescience.com

 

 


Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399

Email: info@opthea.com

Web: www.opthea.com